Trial Radar AI | ||
|---|---|---|
De klinische studie NCT07082062 voor Overgewicht is rekruterend. Bekijk de kaartweergave van de Klinische Studies Radar en de AI-ontdekkingstools voor alle details. Of stel hier een vraag. | ||
Eén studie komt overeen met de filtercriteria
Kaartweergave
Effects of GLP-1 Formula on GLP-1 and Glucose Regulation 100 Gerandomiseerd Crossover Dieet
Informatie over klinische studies is voornamelijk in het Engels beschikbaar. Trial Radar AI kan echter helpen! Klik op 'Leg studie uit' om de informatie over de studie te bekijken en te bespreken in de taal van uw keuze.
De klinische studie NCT07082062 is een interventioneel studie bij Overgewicht met de status rekruterend. Het doel is om 100 deelnemers te includeren vanaf 2 juni 2025. De studie wordt geleid door Shih Chien Huang en de voltooiing is gepland op 31 december 2025. Laatste update op ClinicalTrials.gov: 24 juli 2025.
Beknopte samenvatting
This clinical trial is designed to evaluate the physiological effects of a GLP-1 Formula on glucagon-like peptide-1 (GLP-1) secretion and glycemic regulation in adults with elevated body fat percentage. The GLP-1 Formula is a multi-component dietary supplement composed of Bifidobacterium breve (probiotic), ClpB Formula-a prebiotic blend containing probiotic kombucha extract, soy peptide powder, L-arabinose, and eryth...Toon meer
Uitgebreide beschrijving
This study investigates the physiological effects of a multi-component GLP-1 Formula on incretin secretion and glycemic regulation in overweight adults. GLP-1, a key incretin hormone, plays a critical role in enhancing insulin secretion, suppressing glucagon release, and reducing appetite, making it a promising target in metabolic health modulation. The GLP-1 Formula under investigation includes Bifidobacterium breve...Toon meer
Officiële titel
Exploring the Effects of GLP-1 Formula on GLP-1 Secretion and Postprandial Glucose Regulation
Aandoeningen
OvergewichtAndere studie-ID's
- CS2-24173
NCT-ID
Startdatum (Werkelijk)
2025-06-02
Laatste update geplaatst
2025-07-24
Verwachte einddatum
2025-12-31
Inschrijving (Geschat)
100
Studietype
Interventioneel
FASE
N.v.t.
Status
Rekruterend
Trefwoorden
Probiotic
Prebiotic
Glucagon-like peptide-1 (GLP-1)
Blood glucose
Insulin
Prebiotic
Glucagon-like peptide-1 (GLP-1)
Blood glucose
Insulin
Primaire doel
Preventie
Toewijzing
Gerandomiseerd
Interventiemodel
Cross-over
Blindering
Geen (Open-label)
Armen / Interventies
| Deelnemersgroep/Studiearm | Interventie/Behandeling |
|---|---|
Geen interventieControl group Participants in the control group will consume 100 mL water | N.v.t. |
ExperimenteelGLP-1 formula Group Participants in the intervention group will consume a single dose of GLP-1 formula drink (50 mL) on the study day. The formula includes Bifidobacterium breve (probiotic), ClpB formula (prebiotic), and Rocket Apple extract. | GLP-1 formula Group Participants in the intervention group will consume a single dose of GLP-1 formula drink (50 mL) on the study day. The formula includes Bifidobacterium breve (probiotic), ClpB formula (prebiotic), and Rocket Apple extract. The ClpB formula consists of kombucha, soy peptide powder, L-arabinose and erythritol. |
Primaire uitkomst
| Uitkomstmaat | Beschrijving van de uitkomstmaat | Tijdsbestek |
|---|---|---|
Plasma GLP-1 concentration (pmol/L) | Plasma GLP-1 levels will be measured at fasting and at 15, 30, 45, 60, 90, 120, and 240 minutes after consumption of the GLP-1 Formula on Days 1 and 7. | Day 1 and Day 7 |
Blood glucose concentration (mg/dL) | Blood glucose levels will be measured at fasting and at 15, 30, 45, 60, 90, 120, and 240 minutes after consumption of the GLP-1 Formula on Days 1 and 7. | Day 1 and Day 7 |
Serum insulin concentration (μIU/mL) | Serum insulin levels will be measured at fasting and at 15, 30, 45, 60, 90, 120, and 240 minutes after consumption of the GLP-1 Formula on Days 1 and 7. | Day 1 and Day 7 |
Deelname-assistent
Geschiktheidscriteria
Leeftijd van deelnemers
Volwassene
Minimumleeftijd
18 Years
Geslachten die in aanmerking komen voor de studie
Allen
- Male or female participants aged 18-50 years with a body fat percentage greater than 25%.
- Use of probiotics, weight loss products, or gastrointestinal health-related supplements or medications within the past month.
- Presence of diabetes, autoimmune diseases, cancer, chronic gastrointestinal disorders, lactose intolerance, or chronic diarrhea.
- History of gastrointestinal surgery.
- Pregnant or breastfeeding women.
Shih Chien HuangTCI Co., Ltd.Verantwoordelijke instantie
Shih Chien Huang, Sponsor-Onderzoeker, PhD, Assistant Professor, Chung Shan Medical University
Centraal Contactpersoon
Contact: Shih-Chien Huang, PhD, Associate Professor, +886424730022, [email protected]
1 Studielocaties in 1 landen
Chung Shan Medical University Hospital, Taichung, 402, Taiwan
Shih-Chien Huang, PhD, Associate Professor, Contact, +886424730022, [email protected]
Rekruterend